NONE 7/3/2018 MY MANTRA: SIMPLE, SAFE, CHEAP TWO ITCHY PEARLS ZINC! CONFLICT OF INTEREST DISCLOSURE
|
|
- Jeffrey Sharp
- 5 years ago
- Views:
Transcription
1 TOTALLY RADICAL SYSTEMIC THERAPEUTIC PEARLS {SOMETIMES BASED ON BASICS} {Sometimes Based on Faith} Radical Pearls Hong Kong Jade Market 2014 CONFLICT OF INTEREST DISCLOSURE NONE Ninguno Nessuno Aucun Keiner Ни один 無なし없음 MY MANTRA: SIMPLE, SAFE, CHEAP 70% Psoriasis patients itch ¾ of them itch daily ASPIRIN relieves PsO itch TWO ITCHY PEARLS No-reason itch Negative work up Paroxetine 20mg QD Aropax, Brisdelle, Deroxat, Paxil, Pexeva, Paxtine, Paxetin, Paroxat, Paraxyl, Sereupin, and Seroxat. Skin Therapy Lett 13:6, 2008 ZINC! ZINC: FAST FACTS: LOW ZINC LEVELS ASSOCIATED WITH Immune deficiency: macrophage and neutrophil function, lymphocyte activation / proliferation, complement activity; loss of modulation of TNFα and NO species Delayed wound healing: decreased matrix metalloproteinase activity, decreased keratinocyte migration, increased keratinocyte apoptosis Autoimmun Rev. 2015;14: Wound Repair Regen. 2007;15(1):2-16 1
2 ZINC RX FOR MOLLUSCUM? Open label trial (Korea; n=59) Zinc sulfate 10mg/kg/day (maximum 600mg) Rx done up to 6 months (Mean to success only 4 mo) COMPLETE clearance 47.5% PARTIAL clearance 25.4% CR + PR = 73% Well tolerated (constipation 3%, nausea 1%) ZINC RX FOR VERRUCA? Multiple trials (Korea and Brazil) Zinc sulfate 10mg/kg/day (maximum 600mg) Rx done up to 3 months? MOA; Maybe increases APC activity % success rate reported Failures ascribed to too low a dose, noncompliance due to GI symptoms, or too short treatment regimen Patients do better when serum Zn levels rise by end 1-2mo J Am Acad Dermatol 2016;74(Suppl1):AB162 Br J Dermatol 2002;146:423-31; JAAD 2009;60: ; Ann Bras Dermatol 2009;84:23-29 Clin Exp Dermatol 2009;34:e984-85; J Dermatol 2011;38: ZINC: CAUTION! Warts From Hell Gastritis to gastric perforation; To avoid this. Always give in divided doses Always give after meal Do not exceed mg elemental zinc per day Zinc sulfate: Multiple mg x 23% = elemental Zn Zinc gluconate: Multiply mg x 13% = elemental Zn Six children 9-11yo Recalcitrant warts: palmar or plantar or both Failed: Salicylic acid, Duct tape, Cryo LN 2, Imiquimod, 5-FU, CO 2 laser, Cimetidine 4vHPV x 3 shots (full series) Appropriate age timing for vaccine! Approved and recommended ALL clear non-genital warts (6 of 6) QUADRIVALENT HPV VACCINE EXTRAGENITAL CUTANEOUS WARTS Acta Derm Venereol. 95:1017-9, 2015 HPV VACCINE AND COMMON WARTS 17-yo with idiopathic neutropenia/lymphopenia Multiple common and plantar warts Resistant to cryosurgery, imiquimod, OTCs Given 4vHPV vaccine: after third injection: all warts gone Message: Administration of HPV vaccine (indicated > age 9) may lead to resolution of common/plantar warts Clin Exp Dermatol. 2017;42:
3 HYPERTHERMIA Vasodilation: increased immune cells Upregulates TSLP: recruits immune cells Increased activity T- and B- cells Increased phagocytosis pmn s Increased cytokine release Direct toxic effect on microbes HYPERTHERMIA Sporotrichosis Chromoblastomycosis Leishmaniasis Atypical mycobacteria HSV-1, HSV-2 J Am Acad Dermatol. 2010;62: J Am Acad Dermatol. 2010;62: HYPERTHERMIA AND HSV-1 OR HSV-2 Small handheld device Approved everywhere but USA Emits C heat x 4 seconds 1-2 applications shortens HSV-1 course to 1.85 days (mean) 1-2 applications shortens HSV-2 ~$100; need refills of heat generating cartridge E-Bay, Amazon Praktische Dermatologie. 2011;17: Clin Cosmet Investig Dermatol Jun 5;6:163-6 HYPERTHERMIA AND MOLLUSCUM HEATING PAD Small (n=21) Chinese prospective study; patented IR heating unit 44 0 C (111 0 F) for 30 minutes, once weekly x 12 weeks 13 children, 8 sexually active adults (ages 21-28) Average # lesions = 59 (ie. Bad molluscum) 12/18 complete clearance 12 weeks (children & adults) Facial lesions relatively resistant compared to other sites Br J Dermatol. 2017;176:
4 TINEA VERSICOLOR Stronger warning issued ; Don t use ketoconazole! Alternative orals (off label) Itraconazole 400mg/d x 3d or 200mg/d x 5d J Dermatolog Treat 2002;13:185-7 Fluconazole 300mg QWk x 2 Mycoses 2007;50: VITAMIN D AND INFLAMMATION Vitamin D attaches to both nuclear receptors and transmembrane receptors Alters transcription pattern within cell In general (macrophage/monocyte/lymphocytes) Decreases TNFα, IL-12 Increases IL-4, IL-10 Interaction with mast cells: decreases inflammatory mediator release (histamine, leukotrienes) Histamine, Leukotrienes From mast cells.. HIVES! Int J Biochem Cell Biol. 2011;43:41-6 Exp Dermatol. 2009;18: VITAMIN D RX FOR CHRONIC IDIOPATHIC URTICARIA? Vitamin D levels often low (deficient/insufficient) in CIU IF Vitamin D level < 30ug/L, consider Vitamin D therapy How much? ,000 IU Vitamin D3 daily in literature I give 10,000 IU daily ADJUNCT to typical high dose antihistamine therapy Better response Quicker response Response rates 70+% to 90+% J Dermatolog Treat. 2016;27:163-6 World Allergy Organ J Jun 4;8(1):e15 Dermatoendocrinol Jul 16;6:e29727 Simple, Safe and Cheap Ann Allergy Asthma Immunol. 2014;112: ALOPECIA AREATA 4
5 ALOPECIA AREATA?FEXOFENADINE? Widely utilized in Japan as an adjunctive or even as primary monotherapy Mechanism of action: may prevent mast cell degranulation;? part of AA etiology Simple, safe, cheap: Can be used long term Dose: mg/d (adult) 15-30mg/d (child > 6mo) Available: 30, 60,180mg tab, 30mg/5cc susp and 30mg dissolving tab J Dermatol 39:1063, 2012 J Dermatol 36:323, 2009 J Dermatol 34:852, 2007 COMMON PROBLEM: SENILE (SOLAR) PURURA J Drugs Dermatol 10:718-22, 2011 Arnica montana Ascorbic acid Hesperidin Rutoside Eriocitrin CITRUS BIOFLAVENOIDS Inhibits hyaluronaidase Decreases capillary permeability Collagen synthesis Capillary strength Capillary stability Inhibits elastase Decreases capillary permeability Antioxidant SARCOIDOSIS IF ANTI-MALARIALS, MTX AND STEROIDS FAIL SARCOIDOSIS AND MINOCYCLINE REFERENCE RESPONDED? COMMENT Dermatol Online J 2014 Aug 17;20(8) 1 of 1 Skin only JAMA Dermatol 2013;149: of 27 Skin only J Drugs Dermatol 2012;11: of 1 Hypopigmented Clin Rheumatol 2008;27: of 1 Ocular + Lung Arch Ophthalmol 2007;125: of 1 Ocular + Skin Arch Dermatol 2001;137: of 12 Skin only All at dose of 200mg/day Multiple mechanisms whereby minocycline might be anti-inflammatory in sarcoid (such as TNF-alfa and others), it also directly inhibits granuloma formation Arch Derm 1994;130:
6 SARCOIDOSIS AND INFLIXIMAB Inlfiximab is a chimeric monoclonal antibody which exerts its therapeutic effects by binding to TNF-alfa Infliximab not only binds to free cytokine, but also binds to tissue-bound TNF-alfa (That s why we worry about reactivation of TB, because TNF-alfa is necessary for granuloma formation and maintenance) Logical to administer to a non-infectious disease composed of granulomata STASIS ULCERS SIMVASTATIN AND STASIS ULCERS RCT of Rx chronic ( years) stasis ulcers n= 62 Divided equally: Simvastatin 40mg QD vrs placebo QD Both groups: adequate compression, elevation Ulcers < 5cm: Active Rx 100% versus placebo 50% healed Ulcers > 5cm: Active Rx 67% versus placebo 0% healed Large ulcers took about 9-10 weeks to heal MOA: unknown (?accelerated wound healing) Br J Dermatol 170:1151, 2014 CHONDRODERMATITIS NODULARIS HELICIS Standard therapy: Surgical removal; Topical/IL steroids Open label study (n=11) CNH Nitroglycerin patches 5mg/24hr, 12 hours daily, x 2 months 7/11 (63.6%) complete resolution 2 (18%) stopped Rx due to headache; 1(9%) non-responder MOA: Reversal of ischemia due to vasodilation? Supports prior work w/ nitroglycerin gel (2011) Dermatol Ther 27:278, 2014 HIDRADENITIS: METFORMIN Dermatol Ther 27:278, 2014 Refractory to Rx 25 patients (non-diabetic) Metformin 500mg BID to TID maximum, for 6 mo Majority (18/25) had improved Sartorious score, DLQI and PGA JEADV 27: , 2013 I often add finasteride (men) 5mg/d J Dermatol Treat 16:75-8,
7 HIDRADENITIS: OTHER Refractory to Rx n= 20 patients Open label, prospective 6mo Minocycline 100mg QD Colchicine 0.6mg BID Maintenance only colchicine at prior dosage (3mo) All cleared or improved! Aphthous Ulcers from Hell Int J Dermatol. 2017;56: VITAMIN B12 RCT with 58 patients Minimum 6 attacks/yr 1000mcg sublingual B12 QD vs placebo, 6 mo Active Rx: decreased number aphthae per month, decreased duration of each ulcer, decreased pain associated w/ ulcer By 6 mo, 74% ulcer-free Simple, Safe, Cheap J Am Board Fam Med 22:9, 2009 NICOTINE RAS rare in smokers, maybe because nicotine decreases cytokine and IL production and induces keratinization of oral mucosa Med Hypoth 77:185, 2011 Case report: 39 yo female w/ lifelong severe RAS Failed corticosteroids, colchicine, Abx Thalidomide worked, but developed neuropathy 4.5mg nicotine (lozenges) QD x 14 days, followed by 1.5mg lozenges TID x 6 mo (Australia) RAS-free In USA: 4mg and 2mg lozenges available OTC Australas J Dermatol 56:143, 2015 Hurricane Harvey Hurricane Irma Hurricane Maria HURRICANES AND FLOODS! HOUSTON 7
8 Int J Environ Res Public Health Jun 3;14(6). pii: E594. LEPTOSPIROSIS: CHEMOPROPHYLAXIS Comprehensive review and meta-analysis Doxycycline most widely used drug Single dose 200mg OR 200mg/week for 2-4 weeks PRE-exposure dosage significantly reduces morbidity and mortality POST-exposure dosage trends toward benefit but not statistically significant Int J Environ Res Public Health Jun 3;14(6). pii: E594. FLOOD COMING? TAKE 200MG DOXYCYCLINE! Lancet Infect Dis Dec 8. pii: S (17) Road to my office! POST-EXPOSURE BACTERIAL PROPHYLAXIS? French study; MSM who have condomless sexual contact All receiving PRE-exposure HIV prophylaxis Randomized: Single dose doxycycline 200mg within 24 hours versus no antibiotic within 24 hours of sexual contact (n=116 per group) Followup: 10 mos; Occurrence: chlamydia, GC, syphilis 22% presented with bacterial STD in prophylaxis group 42% presenting with bacterial STD in NO prophylaxis group (p =0.007) Adverse GI events: 53% PEP vs. 41% NO PEP (not stat signif) Lancet Infect Dis Dec 8. pii: S (17) RADICALLY DIFFERENT PEARLS THINK OUTSIDE THE BOX! USE RADICALLY DIFFERENT PEARLS Ted Rosen, MD Professor of Dermatology Baylor College of Medicine Houston, Texas 8
THINKING OUTSIDE THE BOX Ted Rosen, MD Baylor College of Medicine Houston, Texas
THINKING OUTSIDE THE BOX Ted Rosen, MD Baylor College of Medicine Houston, Texas RADICAL TOPICAL THERAPEUTIC PEARLS {SOMETIMES BASED ON BASICS} Hong Kong Jade Market 2014 ZINC! DISCLOSURE OF RELATIONSHIPS
More informationNew and Emerging Therapy Cutaneous Infectious Diseases
New and Emerging Therapy Cutaneous Infectious Diseases Ted Rosen, MD Professor of Dermatology Baylor College of Medicine Houston, Texas Disclosure S062 New and Emerging Therapies Conflict of Interest:
More informationCourse 023 Derm Review No conflicts to declare
What s New in STD: 2018 Conflict of Interest Disclosure Course 023 Derm Review No conflicts to declare TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS Why are STDs Important?
More informationAllergy, Atopy and Skin Cancer
M. Shane Cahpman, MD, MBA: Dartmouth School of Medicine Boni E. Elewski, MD: University of Alabama Kenneth J. Tomecki, MD: Cleveland Clinic Ted Rosen, MD: Baylor College of Medicine Clinical and Therapeutic
More informationS016: Systemic Infections No conflicts for this talk
Adventures in Syphilis Conflict of Interest Disclosure S016: Systemic Infections No conflicts for this talk TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS Objectives Recognize
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationNo conflicts. The Hottest Topic: STDs Conflict of Interest Disclosure. Why are STDs Important?
The Hottest Topic: STDs Conflict of Interest Disclosure No conflicts TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS Why are STDs Important? Left untreated consequences
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationMichael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research
Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research mpheffernanmd@gmail.com DISCLOSURES Consultant, Speaker, Investigator: Abbvie, Amgen, Brickell Biotech,
More informationOrolabial Herpes: Fast Facts. Orolabial Herpes. Relevant Conflict of Interest Disclosure. Epidemiology Caucasian Females
Orolabial Herpes Simplex Old Disease: New Treatments Relevant Conflict of Interest Disclosure Advisory Board with honorarium: Cipher Ted Rosen, MD Professor of Dermatology Baylor College of Medicine Houston,
More informationField vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM
Dilemmas and Challenges in Skin Cancer Therapies and Management Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Roger I. Ceilley, M.D. Clinical Professor of Dermatology The University of Iowa
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To assure that DOP inmates with skin lesions are receiving appropriate Primary Care for their lesions POLICY All DOP Primary Care Providers are expected to follow this guideline and/or
More informationManagement of Chronic Idiopathic Urticaria
9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012
Drug, Treatment, Device name Omalizumab (Xolair; Novartis) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012 Licensed indication Omalizumab
More informationCombination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD
Combination Nonbiologic Therapy in Psoriasis Sushil Tahiliani, MBBS, MD Agenda Rationale Preferred and less preferred combination Morphology-specific preferred combinations Doses used in combinations Potential
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More information4/12/18. Refractory Chronic Urticaria: When Omalizumab Fails. Objectives. Disclosures
Refractory Chronic Urticaria: When Omalizumab Fails David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures n Research Grants n NIH n Honoraria n UpToDate,
More informationThe no t-so-simple cutaneous wart
Salicylic acid is a commonly used over-the-counter treatment for nongenital warts. Clearance rates of up to 75% have been reported with salicylic acid. istockphoto 10 Clinical practice guide Dermatology
More informationINNATE IMMUNITY Non-Specific Immune Response. Physiology Unit 3
INNATE IMMUNITY Non-Specific Immune Response Physiology Unit 3 Protection Against Infection The body has several defenses to protect itself from getting an infection Skin Mucus membranes Serous membranes
More informationVITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY
VITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY VIT D RECEPTORS ROLE IN MAINTAINING NORMAL FOLLICULAR
More informationMegha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, MFMER
Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics, Mayo Clinic Pediatric Morphea March 1, 2019 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Topics to cover Classification
More informationChapter 11. Sexually Transmitted Diseases
Chapter 11. Sexually Transmitted Diseases General Guidelines Persons identified as having one sexually transmitted disease (STD) are at risk for others and should be screened as appropriate. Partners of
More informationThings that go bump: Wart & Molluscum
Things that go bump: Wart & Molluscum Raegan Hunt, MD, PhD Chief of Section, Pediatric Dermatology Texas Children s Hospital Disclosures Off label use of products may be discussed No relevant financial
More informationHPV Management in Special Populations
HPV Management in Special Populations MELISSA KOTTKE, MD, MPH, MBA Disclosures Merck, Nexplanon trainer CSL Behring, Consultant Evofem, Advisory Board Most treatment options for HPV in special populations
More informationFRM F011 - Pearls: Diagnostic and Therapeutic
FRM F011 - Pearls: Diagnostic and Therapeutic I have uploaded these slides as a handout, and will replace them with the ones actually used in the presentation when I get home or you can email me at sstone@siumed.edu
More informationReview Acne Pathogenesis Clinical Evaluation Treatment Guidelines
Tiffany Herd, MD Pediatric Dermatology Fellow Baylor College of Medicine/Texas Children's Hospital Review Acne Pathogenesis Clinical Evaluation Treatment Guidelines Psychosocial Impact of Acne Acne is
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma,
More informationDeep Dermatophytosis
Deep Dermatophytosis 2016-11-06 MMTN/Bangkok Department of Dermatology Chang Gung Memorial Hospital, Linkou Branch Taoyuan, Taiwan Superficial dermatophytosis Wikimedia Stratum corneum Tinea faciei Tinea
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationHow to Successfully Manage Chronic Urticaria? & Tall Tales from Texas
How to Successfully Manage Chronic Urticaria? & Tall Tales from Texas David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures Honoraria/Speakers Bureau
More informationAnti-TNF biologic agents Dr Lluís Puig
Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Anti-TNF biologic agents Dr Lluís Puig Barcelona, July 9th-10th, 2013 Anti-TNF therapy in the pathophysiology
More informationCOMPLEX CUTANEOUS LUPUS CASES PEARLS AND PITFALLS
COMPLEX CUTANEOUS LUPUS CASES PEARLS AND PITFALLS Benjamin F. Chong, MD, MSCS February 17, 2018 CONFLICTS OF INTEREST D I S CLOSURE OF R E LATI ONSHIPS W I T H I NDUSTRY Benjamin Chong, MD, MSCS F059 Complex
More informationComparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine Advisory Committee on Immunization Practices 24-Feb-2016
1 Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine Advisory Committee on Immunization Practices 24-Feb-2016 Presenter: Alain Luxembourg, MD, PhD Director, Clinical Research
More informationUpdate on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH
Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Division of Infectious Diseases University of Alabama at Birmingham School of Medicine Birmingham, Alabama Outline Syphilis in all its
More informationAnswers to those burning questions -
Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department
More informationWhy the basics? Back to Basics HIV Dermatology Immune reconstitution Acne. The HIV infected pt who starts ARV s 12/12/2012
Why the basics? Back to Basics HIV Dermatology 2012 Toby Maurer, MD University of California, San Francisco 1) The depleted low CD4 counts 2) The repleted aging pts 3) The group who starts ARV s at high
More informationOPPORTUNISTIC INFECTIONS. Institute of Infectious Diseases, Pune India
OPPORTUNISTIC INFECTIONS Institute of Infectious Diseases, Pune India DISCLOSURES Nothing to declare Outline The problem Bacterial Fungal Protozoal Viral Decline in OI prevalence in HAART era: USA CROI
More informationMedical Dermatology Highlights Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center
Medical Dermatology Highlights 2017 Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center I have no relevant financial relationships with commercial interest(s).
More informationTinea: Head to Toe A dermatophyte tour of human skin. Tour de Tinea Head to Toe. Tips for Tinea Head to Toe. Psoriasis. Non-inflammatory Tinea Capitis
Tinea: Head to Toe A dermatophyte tour of human skin Renee Howard, MD Assistant Clinical Professor of Dermatology, UCSF Tour de Tinea Head to Toe Tips for Tinea Head to Toe Capitis Faciei Corporis Pedis
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationImmunology. Lecture- 8
Immunology Lecture- 8 Immunological Disorders Immunodeficiency Autoimmune Disease Hypersensitivities Immunodeficiency 1. Immunodeficiency --> abnormal production or function of immune cells, phagocytes,
More informationThe Great Imitator Revealed: Syphilis
The Great Imitator Revealed: Syphilis Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles David Geffen School of Medicine Los Angeles, California Learning
More informationRight type of lesions for topicals. Onychomycosis. Common Diseases and Infections of the SKIN. Toby Maurer, MD University of California, San Francisco
Common Diseases and Infections of the SKIN Toby Maurer, MD University of California, San Francisco Onychomycosis Topical treatment use for the right type of lesions Naftin gel for small superficial lesions
More informationEmerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment
9 th Annual New Cardiovascular Horizons New Orleans September 12, 2008 Emerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment Gary M. Rothenberg, DPM, CDE,
More informationContents. QAaptm-2. CAaptei-3. CAaptm-4. Cftapte%-5. Qfiaptvt-6. QhapteK-7. Qkaptefc-8 Clinical Immunology and Allergy 71
Contents Ckaptm-1 Aaatomy, Physiology, Embryology, Bacteriology and Pathology ~ 1 Anatomy 1 Physiology 10 Embryology 14 Pathology 19 Bacteriology 22 Laboratory and other aids in dermatological pratice
More informationMechanisms of disease
PP Mechanisms of disease Stress and disease Homeostasis - Responsible for maintaining a constant, safe internal environment - Controlled by feedback loops o Negative feedback loop: temperature, blood glucose
More informationOsteopathic Dermatology
Osteopathic Dermatology Teodor Huzij, DO, FACN Reagan Anderson, DO, FAOCD, FASMS, Certificate of Added Qualification for Mohs Surgery, MPH, MCS, Program Director for RVU/CDI Dermatology Residency Program
More informationAnaphylactic response in rabbit Part II
Anaphylactic response in rabbit Part II Introduction Four types of hypersensitivity reactions: Type I: allergy Type II: antibodies Type III: immune complex Type IV: T-cells Type I Hypersensitivity ALLERGY
More informationResurgence of (many) STDs
Resurgence of (many) STDs TED ROSEN, MD PROFESSOR OF DERMATOLOGY BAYLOR COLLEGE OF MEDICINE HOUSTON, TEXAS 1 Conflict of Interest NONE 2 1 Resurgent STDs Carnival Las Tablas, Republic of Panama 3 4 2 Sex
More informationNew Drugs for Uveitis. Medical Eye Unit St Thomas Hospital
New Drugs for Uveitis Miles Stanford Medical Eye Unit St Thomas Hospital x Epithelium x x Antigen Y Y Y Y IgG m cd4 IL-2 Y m + IL-12 Cytotoxic T B pmn Ig s PG s. LTB4 O - IL-6 TNFα IFNγγ IL-2 Th1 IL-10
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationAndrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada
Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses Inc. All rights reserved.
More informationBL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS
BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS 25 Skin lesions Miri Seiberg, PhD 26 Skin lesions A part of the skin that has an abnormal growth or appearance compared
More informationInteresting Case Series. Skin Grafting in Pyoderma Gangrenosum
Interesting Case Series Skin Grafting in Pyoderma Gangrenosum Marco Romanelli, MD, PhD, Agata Janowska, MD, Teresa Oranges, MD, and Valentina Dini, MD, PhD Department of Dermatology, University of Pisa,
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationDermatopathology Case Challenge: Recognizing Mimics and Masqueraders
Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH
More informationBugs and Drugs: What s New in Hypersensitivity Reactions?
Bugs and Drugs: What s New in Hypersensitivity Reactions? Erin Mathes, MD Associate Professor of Dermatology and Pediatrics University of California, San Francisco DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationNon-Steroidal Anti- Inflammatory Drugs. ATPE 410 Chapter 6
Non-Steroidal Anti- Inflammatory Drugs ATPE 410 Chapter 6 Inflammatory Process A normal, beneficial process that begins immediately after injury to facilitate repair and return the tissue to normal function
More informationEvolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target
Evolving therapies for posterior uveitis Sam Dahr, M.D. September 17, 2005 Midwest Ophthalmology Conference Infliximab (Remicade) FDA approved for Crohn s disease, rheumatoid arthritis, and psoriatic arthritis
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationTreatment Options for Refractory Urticaria
Treatment Options for Refractory Urticaria David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology University of Texas Southwestern Medical Center
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationAtopic Dermatitis: Therapeutic Challenges
Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction
More informationDISCLOSURES WHAT S NEW AND EXCITING FROM JAAD
WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT
More informationWound Healing Stages
Normal Skin Wound Healing Stages Stages overlap Chronic wounds are stalled in the inflammatory phase COLLAGEN MATURATION MATRIX METALLOPROTEINASES ENDOTHELIAL CELLS EPITHELIAL CELLS MATRIX PROTEINS FIBROBLASTS
More informationSystemic Medications for the Dermatology Toolbox: Potassium Iodide Handout for Key Points
Systemic Medications for the Dermatology Toolbox: Potassium Iodide Handout for Key Points Taraneh Paravar, MD Assistant Professor Department of Dermatology, UC San Diego March 3, 2017 DISCLOSURE OF RELATIONSHIPS
More information12/12/2018. Childhood Skin Infections. Objectives. Verruca vulgaris. Case #1. Case #2. Management 1. Evidence Updates
Objectives Childhood Skin Infections Evidence Updates Brian Z. Rayala, MD Associate Professor Department of Family Medicine UNC School of Medicine At the end of lecture, learner will be able to:» Diagnose
More informationFungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection
Fungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection Faculty Raza Aly, PhD, MPH Professor Emeritus University of California Medical Center (MSSF) Professor, Dermatology Faculty
More informationCutaneous warts are one of the most common
A Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions
More informationImmunotherapy of Warts
Immunotherapy of Warts Jacob Mashiah, MD, MHA Dermatology and Pediatric Dermatology Dana-Dowek children s hospital Sourasky Medical Center Tel-Aviv, Israel No conflict of interest to disclose Human Papillomavirus
More informationREPRINT REPRIN REPRINT REP. Cutaneous warts are one of the most common
A Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions
More informationMeds and Falls: Keep in Step with your Meds
Meds and Falls: Keep in Step with your Meds Donna Bartlett PharmD, CGP, RPh Associate Professor-Pharmacy Practice MCPHS University Clinical Pharmacist-MCPHS University- Pharmacy Outreach Program donna.bartlett@mcphs.edu
More informationTreatment with steroids and immunosuppressants
Treatment with steroids and immunosuppressants Donna Culton, MD, PhD University of North Carolina IPPF 2017 Annual Patient Conference Newport Beach, CA September 16, 2017 Factors that will influence therapy
More informationItraconazole DIGICON. Composition: MOLECULAR INTRODUCTION
Itraconazole DIGICON Composition: Itraconazole 100 mg MOLECULAR INTRODUCTION Itraconazole is a triazole medicine used to treat fungal infections. It is effective against a broad spectrum of fungi including:
More informationThe Skinny of the Immune System
The Skinny of the Immune System Robert Hostoffer, DO, FACOP, FAAP Associate Professor of Pediatrics Case Western Reserve University, Cleveland, Ohio Overview 1. Immune system of the skin 2. Immune Players
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationBIOH122 Session 8 Non-Specific Disease Resistance
BIOH122 Session 8 Non-Specific Disease Resistance To complete this worksheet, select: Module: Disease Resistance Activity: Animations Title: Non-Specific Disease Resistance Introduction 1. Name five general
More informationInnate vs Adaptive Response
General Immunology Innate vs Adaptive Response Innate- non-specific (4 types of barriers) anatomic- ato mechanical ca (skin), ph, mucous, normal flora Physiologic- temperature, ph, chemicals (lysozyme,
More informationINFLAMMATION & REPAIR
INFLAMMATION & REPAIR Lecture 7 Chemical Mediators of Inflammation Winter 2013 Chelsea Martin Special thanks to Drs. Hanna and Forzan Course Outline i. Inflammation: Introduction and generalities (lecture
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationStevens-Johnson s Syndrome / Toxic Epidermal Necrolysis: An update
Stevens-Johnson s Syndrome / Toxic Epidermal Necrolysis: An update Robert G. Micheletti, MD Assistant Professor of Dermatology and Medicine Director, Cutaneous Vasculitis Clinic, Penn Vasculitis Center
More informationTable of Contents. Injectable Gel with 0.3% Lidocaine
Patient Brochure Table of Contents About Restylane-L 4 Safety 6 Post-Marketing Surveillance 9 About the Procedure 10 Troubleshooting 11 Injectable Gel with 0.3% Lidocaine 2 3 About Restylane-L Q What is
More informationEGFR inhibitors. EGFR inhibitors. Cutaneous side effects of EGFRinhibitors. EGFR inhibitor skin toxicity. EGFR is abundantly expressed in the skin
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of EGFRinhibitors and their management Siegfried Segaert Dermatology Dept University Hospital Leuven Belgium
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationAsymptomatic Undiagnosed Lichen Sclerosus
Asymptomatic Undiagnosed Lichen Sclerosus Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology) Geisel School of Medicine at Dartmouth Lebanon, NH, USA Disclosures
More information2/18/19. Case 1. Question
Case 1 Which of the following can present with granulomatous inflammation? A. Sarcoidosis B. Necrobiotic xanthogranulma C. Atypical mycobacterial infection D. Foreign Body Reaction E. All of the above
More informationUveitis unplugged: systemic therapy
Uveitis unplugged: systemic therapy Hobart 2017 Peter McCluskey Save Sight Institute Sydney Eye Hospital Sydney Medical School University of Sydney Sydney Australia No financial or proprietary interest
More informationIL-17 in health and disease. March 2014 PSO13-C051n
IL-17 in health and disease March 2014 PSO13-C051n Originally Researchers Suggested That IL-12 and IL-4 drove Th Cell Differentiation Naïve CD4 + T cell Question: Which of these cell types is responsible
More informationCutaneous Immunology: Innate Immune Responses. Skin Biology Lecture Series
Cutaneous Immunology: Innate Immune Responses Skin Biology Lecture Series The Immune Response: Innate and Adaptive Components Source: Wolff, Goldsmith, Katz, Gilchrest, Paller, Leffell. Fitzpatrick s Dermatology
More informationAn Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More information5/1/2017. Sexually Transmitted Diseases Burning Questions
Sexually Transmitted Diseases Burning Questions Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Los Angeles, California FORMATTED: 04-03-17 Financial
More informationCase 1 History. William Tremaine, M.D. CP
Extraintestinal Manifestations of IBD Case Studies William Tremaine, M.D. Case 1 History 18 year-old woman with Crohn s disease Onset at age 5: colonic & perianal Sulfasalazine, prednisone, mercaptopurine
More informationMUCOCUTANEOUS MANIFESTATIONS OF HIV/AIDS IN ADOLESCENTS
MUCOCUTANEOUS MANIFESTATIONS OF HIV/AIDS IN ADOLESCENTS Dr. Y.S.MARFATIA Prof. and Head, Dept. Skin & V.D. Medical college, Vadodara LET US CREATE BRILLIANCE TOGETHER MEDICAL COLLEGE, VADODARA Editor in
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More information